Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.30 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5774973 | 0.88 | SLC2A1 (0.32) | CRHR1SLC2A1 | |
| Trifluoroacetic Acid SCHEMBL5773559 | 0.86 | KCNK3 (0.31) | CRHR1 | |
| SCHEMBL5045280 | 0.75 | CRHR1 (0.33) | CRHR1 | |
| Trifluoroacetic Acid SCHEMBL5514719 | 0.72 | CRHR1 (0.35) | CRHR1SLC2A1 | |
| SCHEMBL5517704 | 0.72 | MAP3K14 (0.30) | — | |
| SCHEMBL5047526 | 0.72 | ESR1 (0.34) | CRHR1 | |
| Trifluoroacetic Acid SCHEMBL5517788 | 0.71 | CRHR1 (0.36) | CRHR1 | |
| Trifluoroacetic Acid SCHEMBL5518248 | 0.71 | CRHR1 (0.34) | CRHR1 | |
| Trifluoroacetic Acid SCHEMBL5519893 | 0.70 | CRHR1 (0.36) | CRHR1 | |
| Trifluoroacetic Acid SCHEMBL5047423 | 0.70 | TP53 (0.41) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453832-B1 | RING FUSED PYRAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-20060135555-A1 | (3,4-Dihydro-1H-isoquinolin-2-yl)-[2-methyl-7-(2,4,6-trimethyl-phenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-b]pyridin-3-yl]-methanone; Corticotropin releasing factor (CRF); stress-related illnesses, mood disorders such as depression, major depressive disorder, single episode depression | ROCHE PALO ALTO LLC | 2006-06-22 | — | — | US | disclosed |
| US-20050014781-A1 | Ring fused pyrazole derivatives as CRF antagonists | LOUGHHEAD DAVID GARRETT (US) | 2005-01-20 | — | — | US | disclosed |
| US-6821984-B2 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES | SYNTEX (U.S.A.) LLC | 2004-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135555-A1 | (3,4-Dihydro-1H-isoquinolin-2-yl)-[2-methyl-7-(2,4,6-trimethyl-phenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-b]pyridin-3-yl]-methanone; Corticotropin releasing factor (CRF); stress-related illnesses, mood disorders such as depression, major depressive disorder, single episode depression | CRHR1, CRH, CRHR2 | PRCP 1867/4885CRHR1 1/4885SLC2A1 4333/4885 |
| US-20050014781-A1 | Ring fused pyrazole derivatives as CRF antagonists | CRHR1, CRHR2, MC2R | PRCP 601/4885CRHR1 1/4885SLC2A1 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.